Chemo-immunotherapy Induction Followed by Hypo-radiotherapy in LA-NSCLC(CHIC)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

October 27, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2027

Conditions
Lung Cancer, Non-small Cell
Interventions
RADIATION

hypofractionated radiation therapy

"* Part 1: Patients who have received induction immunotherapy plus chemotherapy for 2-6 cycles and met the hypoRT criteria will be enrolled into the study.~* Part 2: patients will be treated with hypofractionated radiation therapy in doses up to 48-60 Gy at 4 Gy per fraction.~* Part 3: patients with partial response or stable disease after part 2 will be eligible for immunotherapy maintenance, for up to 1 years or until disease progression or unacceptable toxicity."

Trial Locations (1)

210009

Jiangsu Cancer Hospital, Nanjing

All Listed Sponsors
lead

Jiangsu Cancer Institute & Hospital

OTHER